Your browser is no longer supported. Please, upgrade your browser.
Settings
MRKR Marker Therapeutics, Inc. daily Stock Chart
MRKR [NASD]
Marker Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.22 Insider Own13.40% Shs Outstand39.71M Perf Week9.17%
Market Cap208.08M Forward P/E- EPS next Y-0.54 Insider Trans- Shs Float31.21M Perf Month-9.50%
Income-150.10M PEG- EPS next Q-0.13 Inst Own38.70% Short Float15.11% Perf Quarter-9.66%
Sales0.20M P/S1040.40 EPS this Y-567.10% Inst Trans13.17% Short Ratio6.66 Perf Half Y-11.49%
Book/sh1.22 P/B4.30 EPS next Y-3.80% ROA-443.60% Target Price13.08 Perf Year-30.60%
Cash/sh1.45 P/C3.61 EPS next 5Y- ROE-494.10% 52W Range3.97 - 10.60 Perf YTD-5.59%
Dividend- P/FCF- EPS past 5Y33.20% ROI-249.90% 52W High-50.57% Beta0.27
Dividend %- Quick Ratio19.70 Sales past 5Y- Gross Margin- 52W Low31.99% ATR0.48
Employees11 Current Ratio19.70 Sales Q/Q- Oper. Margin- RSI (14)46.55 Volatility8.62% 8.41%
OptionableYes Debt/Eq0.00 EPS Q/Q61.10% Profit Margin- Rel Volume0.33 Prev Close5.56
ShortableYes LT Debt/Eq0.00 EarningsAug 08 Payout- Avg Volume707.77K Price5.24
Recom1.70 SMA208.18% SMA50-18.58% SMA200-14.03% Volume234,201 Change-5.76%
May-30-19Initiated ROTH Capital Buy
Mar-01-19Initiated Janney Buy
Dec-03-18Upgrade Piper Jaffray Neutral → Overweight
Aug-15-19 04:01PM  Marker Therapeutics Appoints Nadia Agopyan, Ph.D., RAC as Vice President of Regulatory Affairs PR Newswire
Aug-08-19 04:01PM  Marker Therapeutics Reports Second Quarter 2019 Operating and Financial Results PR Newswire -5.71%
12:04PM  Do Insiders Own Shares In Marker Therapeutics, Inc. (NASDAQ:MRKR)? Simply Wall St.
Aug-06-19 04:05PM  Marker Therapeutics Appoints Steve Elms to its Board of Directors PR Newswire
Jul-20-19 11:00AM  Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR PR Newswire
Jul-17-19 07:00AM  Marker Therapeutics to Host Conference Call and Webcast to Review Interim Results from Phase 1/2 Clinical Trial with its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma PR Newswire
Jun-28-19 06:01PM  Hedge Funds Have Never Been This Bullish On Marker Therapeutics, Inc. (MRKR) Insider Monkey
Jun-20-19 07:00AM  Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma PR Newswire +8.19%
Jun-13-19 06:08AM  Will Marker Therapeutics Surge Higher? Zacks
May-21-19 07:00AM  Marker Therapeutics to Present at Two Upcoming Investor Conferences PR Newswire
May-10-19 01:47PM  Should Marker Therapeutics (NASDAQ:MRKR) Be Disappointed With Their 89% Profit? Simply Wall St. +7.53%
May-09-19 05:55PM  MARKER THERAPEUTICS, INC. (MRKR) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM  Marker Therapeutics Reports First Quarter 2019 Operating and Financial Results PR Newswire
May-07-19 04:10PM  Marker Therapeutics to Present at the Bank of America Merrill Lynch Health Care Conference PR Newswire
Apr-17-19 12:22PM  Here's Why Marker Therapeutics Fell as Much as 11.5% Today Motley Fool
Mar-29-19 10:22AM  Zacks.com featured expert Kevin Matras highlights: Methode Electronics, Walker & Dunlop, Marker Therapeutics, Chemed and Olympic Steel Zacks +9.45%
Mar-28-19 04:05PM  Marker Therapeutics Provides Business and Clinical Update PR Newswire -10.13%
08:10AM  These 5 Stocks Make Great Buys on New Analyst Coverage Zacks
Mar-18-19 07:00AM  Marker Therapeutics to Host Business Update Conference Call and Webcast on Thursday, March 28th PR Newswire
Feb-25-19 07:00AM  Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019 PR Newswire +8.78%
Feb-21-19 06:00PM  Marker Therapeutics Congratulates Helen E. Heslop, MD, DSc (Hon) on Receiving the ASBMT Lifetime Achievement Award PR Newswire
Feb-20-19 07:00AM  Marker Therapeutics to Present at the CAR-TCR Summit Europe PR Newswire
Feb-15-19 04:30PM  Marker Therapeutics Announces Change in Corporate Headquarters and Access to New Laboratory Facility PR Newswire
Feb-07-19 07:00AM  Marker Therapeutics Appoints Mythili Koneru, M.D., Ph.D. as Senior Vice President, Clinical Development PR Newswire
Feb-06-19 07:00AM  Marker Therapeutics to Present at the 2019 BIO CEO & Investor Conference PR Newswire
Feb-04-19 10:26AM  Does Market Volatility Impact Marker Therapeutics, Inc.s (NASDAQ:MRKR) Share Price? Simply Wall St.
Jan-17-19 07:00AM  Marker Therapeutics to Present at the Phacilitate Leaders World & World Stem Cell Summit 2019 PR Newswire
Jan-15-19 04:30PM  The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019 PR Newswire
Jan-03-19 04:36PM  Marker Therapeutics Provides Updates of its Lead Clinical Programs PR Newswire -5.48%
Dec-31-18 01:50PM  These 4 Healthcare Stocks May Test December Highs ACCESSWIRE +16.35%
Dec-06-18 07:00AM  Marker Therapeutics to Present at the Tumor Targeted Lymphocytes Summit PR Newswire
Nov-27-18 04:32PM  The Center for Cell and Gene Therapy at Baylor College of Medicine to Present at the 60th American Society of Hematology Annual Meeting PR Newswire
07:00AM  Marker Therapeutics, Inc. Appoints Anthony H. Kim as Chief Financial Officer PR Newswire
Nov-08-18 06:30AM  Marker Therapeutics to Present at Three Upcoming Healthcare Conferences PR Newswire
Oct-23-18 04:30PM  Marker Therapeutics, Inc. Announces New Executive Appointments PR Newswire -12.31%
Oct-22-18 08:30AM  True Nature Holding Inc. Strengthens Board of Advisors With Appointment of Michael J. Loiacono GlobeNewswire -6.21%
Oct-18-18 06:30AM  Marker to Present at Two Upcoming Cellular Therapy Conferences PR Newswire
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. In addition, the company is developing PolyStart, a proprietary nucleic acid-based antigen expression technology to enhance the ability of the immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.